Xytrin-M Tablet is a combination medication containing Levocetirizine 5 mg and Montelukast 10 mg, formulated for the effective management of allergic conditions. Levocetirizine, a third-generation non-sedative antihistamine, selectively inhibits peripheral H1 receptors, thereby alleviating symptoms such as rhinorrhea, sneezing, nasal congestion, and itching associated with allergic rhinitis and chronic urticaria. Montelukast, a leukotriene receptor antagonist, blocks the action of cysteinyl leukotrienes, which are inflammatory mediators involved in bronchoconstriction, mucus secretion, and airway edema, making it beneficial in the prophylaxis and chronic treatment of asthma and allergic rhinitis. The synergistic effect of these two active ingredients provides comprehensive relief from both upper and lower respiratory allergic manifestations. Xytrin-M is indicated for patients requiring combined antihistaminic and leukotriene receptor antagonist therapy to improve symptom control and quality of life. It is generally well-tolerated; however, patients should be monitored for potential adverse effects such as headache, fatigue, gastrointestinal disturbances, or neuropsychiatric events. Dosage should be as prescribed by a healthcare professional, considering individual patient needs and clinical response. Xytrin-M offers a convenient once-daily oral dosing regimen, enhancing patient compliance in the management of allergic disorders.